Inflexion brings a number of strengths to our business, firstly a challenging mindset stimulating management to think about being more ambitious. They are agile but approachable. There is access to additional funding and to their network which is important in identifying opportunities on the M&A front.

Howard Taylor CEO, Rosemont Pharmaceuticals

About  

Rosemont Pharmaceuticals’ impressive organic and acquisitive growth has seen annual turnover more than double and EBITDA triple since the Inflexion-led carve-out from a US-listed parent in 2020.  

Rosemont is the UK’s leading liquid generic pharmaceutical platform, selling life-saving oral liquid medicines to those with swallowing difficulties (primarily geriatric and paediatric patients). The company commands more than half of the UK market and is the sole supplier of a total of 27 unique molecules in the UK, with a portfolio of over 130 oral liquid medicines into the UK as well as the US, Continental Europe and the Middle East. 

Value acceleration  

With substantial experience in successfully executing carve-outs, we have drawn on our healthcare expertise to establish Rosemont as a fully standalone business. We leveraged our digital experience to assist with the IT carve-out and invested further in innovation and new product development, driving a pipeline of c.70 new products expected to launch by 2029. The c-suite build out was supported by Inflexion’s talent team and with four completed bolt-ons in the UK, US and Greece. Inflexion continues to support with international growth, including the hiring of a US Vice President to drive our US business.

Inflexion brings a number of strengths to our business, firstly a challenging mindset stimulating management to think about being more ambitious. They are agile but approachable. There is access to additional funding and to their network which is important in identifying opportunities on the M&A front.

Howard Taylor CEO, Rosemont Pharmaceuticals